Niche Portfolio

As a niche portfolio, the company has selected only the highest volume and highest value generic pharmaceuticals.

As the patents of many of the top 50 drugs continue to expire over the coming years, the company's niche portfolio will represent a significant portion of the value of all generics.

The companies current range of PBS products represents around 30% of the value of all PBS generics.

In addition to the products currently available, the company has a number of products currently being evaluated by the TGA for approval as well as a pipeline of drugs under development. Product details will be made available closer to products being available for sale.

Specific product details will be released closer to the date of first sales.